Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

TEVA Teva Pharmaceutical Industries Ltd

17,63

0,98 (5,89%)

Última atualização: 16:17:14

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

3 E SHARES OUTSTANDING BASED ON ORDINARY SHARES AS OF SEPTEMBER 30 24 SHARES SOLD WERE TO COVER OBLIGATIONS UNDER A 10B5 1 PLAN DIRECTIVE

Date of Notice

11/20/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

CONFORMED SIGNATURE ON FILE

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Click aqui para mais gráficos Teva Pharmaceutical Indu....

Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024

Click aqui para mais gráficos Teva Pharmaceutical Indu....

Notícias Teva Pharmaceutical Industries Ltd

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Segunda, 25 de Novembro de 2024 (1 semana atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 21 de Novembro de 2024 (2 semanas atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quarta, 20 de Novembro de 2024 (2 semanas atrás) • Edgar (US Regulatory)

Teva to Present at the Jefferies London Healthcare Conference
Sexta, 8 de Novembro de 2024 (4 semanas atrás) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Quarta, 6 de Novembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quarta, 6 de Novembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Quarta, 6 de Novembro de 2024 (4 semanas atrás) • GlobeNewswire Inc.

U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength
Quarta, 6 de Novembro de 2024 (4 semanas atrás) • IH Market News

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Sexta, 1 de Novembro de 2024 (1 mês atrás) • GlobeNewswire Inc.

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R
Sexta, 1 de Novembro de 2024 (1 mês atrás) • GlobeNewswire Inc.

Teva Statement on European Commission Decision; Company to Appeal
Quinta, 31 de Outubro de 2024 (1 mês atrás) • GlobeNewswire Inc.

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Terça, 22 de Outubro de 2024 (1 mês atrás) • GlobeNewswire Inc.

Mais Notícias de Teva Pharmaceutical Industries Ltd

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições